ProAlt is developing a test for early screening of colorectal cancer in medium and high risk populations. This test is based on analyzing a person’s blood to detect autoantibodies related with the disease. The test will be developed based on a standard ELISA format, allowing rapid and simple detection of colorectal cancer from blood samples. Screening of populations with this test will achieve earlier detection of a greater number of patients, which will involve better treatment options to improve patient’s survival.
The diagnostic test in development by ProAlt offers an interesting alternative for early detection of colon cancer with some potential advantages compared to traditional technologies, such as simplicity in applications, detection accuracy and low cost. The main characteristics of the ProAlt’s test in development are:
ProAlt also works, through its own research, in the identification and verification of new biomarkers of glioblastoma. The company is studying differences in auto-antibodies composition of biological fluids from different patient groups. Potential biomarkers will be validated by checking the presence or absence in larger groups of people (e.g. healthy and sick) to refine the validity of biomarkers and select those most useful.
ProAlt´s business model & pipeline in diagnostic kits